Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025)
Avalo Therapeutics' (AVTX) quarterly EBT Margin came in at 23033.9% in Q4 2025, down 468754.0% YoY from N/an in Q4 2024, and down 25.55% on a QoQ basis from 18346.35% in Q4 2024.
Powered by 
Analysis
Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of EBT Margin data on file, last reported at 23033.9% in Q4 2025.
- Quarterly EBT Margin fell 468754.0% year-over-year to 23033.9% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 15618.8% (down 767889.0% YoY) and the FY2025 annual result came in at 132362.71%, down 12442280.0% from the prior year.
- EBT Margin fell to 23033.9% in Q4 2025, from 18346.35% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 9246.18% in Q3 2024 to a low of 23033.9% in Q4 2025.
- A 5-year average of 4024.64% and a median of 1432.05% in 2023 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 1145805 bps in 2024, down 1691431 bps in 2024.
- Tracing AVTX's EBT Margin over 5 years: stood at 8742.92% in 2021, then surged by 87 bps to 1094.2% in 2022, then tumbled by 31 bps to 1432.05% in 2023, then sank by 1181 bps to 18346.35% in 2024, then retreated by 26 bps to 23033.9% in 2025.
- The last three EBT Margin figures came in at 23033.9% (Q4 2025), 18346.35% (Q4 2024), and 9246.18% (Q3 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -23,033.90% |
| Dec 31, 2024 | -18,346.35% |
| Sep 30, 2024 | 9,246.18% |
| Dec 31, 2023 | -1,432.05% |
| Sep 30, 2023 | -2,211.86% |
| Jun 30, 2023 | -1,273.09% |
| Mar 31, 2023 | -2,094.11% |
| Dec 31, 2022 | -1,094.20% |
| Sep 30, 2022 | 21.39% |
| Jun 30, 2022 | -1,256.73% |
| Mar 31, 2022 | -1,879.11% |
| Dec 31, 2021 | -8,742.92% |
| Sep 30, 2021 | -1,293.56% |
| Jun 30, 2021 | -517.82% |
| Mar 31, 2021 | -6,461.52% |
| Dec 31, 2020 | -1,090.71% |
| Sep 30, 2020 | -1,193.34% |
| Jun 30, 2020 | -992.53% |
| Mar 31, 2020 | -882.79% |
| Dec 31, 2019 | -974.36% |